Skip to main content

The COAST-X trial

COAST-X trial published: IL-17A inhibition may be beneficial for nonradiographic axSpA

Tuesday 12 November: 11:00–12:30, Hall B1, Georgia World Congress Center, Atlanta, USA

Presenter: Atul Deodhar, Oregon Health & Science University, Portland, USA

COAST-X is a 52-week, phase III trial of ixekizumab versus placebo in 303 patients with active non-radiographic axial spondyloarthritis and an inadequate response or intolerance to NSAIDs. The patients were given one of two ixekizumab doses – 80 mg every 4 weeks or 80 mg every 2 weeks – or placebo. The primary endpoints were ASAS40 response at weeks 16 and 52.

Back to the ACR/ARP 2019 conference hub